1. Home
  2. ADTX vs XRTX Comparison

ADTX vs XRTX Comparison

Compare ADTX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADTX
  • XRTX
  • Stock Information
  • Founded
  • ADTX 2017
  • XRTX 2011
  • Country
  • ADTX United States
  • XRTX Canada
  • Employees
  • ADTX N/A
  • XRTX N/A
  • Industry
  • ADTX Biotechnology: Pharmaceutical Preparations
  • XRTX Pharmaceuticals and Biotechnology
  • Sector
  • ADTX Health Care
  • XRTX Health Care
  • Exchange
  • ADTX Nasdaq
  • XRTX Nasdaq
  • Market Cap
  • ADTX 3.1M
  • XRTX 3.4M
  • IPO Year
  • ADTX 2020
  • XRTX N/A
  • Fundamental
  • Price
  • ADTX $1.19
  • XRTX $0.80
  • Analyst Decision
  • ADTX
  • XRTX
  • Analyst Count
  • ADTX 0
  • XRTX 0
  • Target Price
  • ADTX N/A
  • XRTX N/A
  • AVG Volume (30 Days)
  • ADTX 466.9K
  • XRTX 73.5K
  • Earning Date
  • ADTX 08-18-2025
  • XRTX 08-18-2025
  • Dividend Yield
  • ADTX N/A
  • XRTX N/A
  • EPS Growth
  • ADTX N/A
  • XRTX N/A
  • EPS
  • ADTX N/A
  • XRTX N/A
  • Revenue
  • ADTX $55,323.00
  • XRTX N/A
  • Revenue This Year
  • ADTX $15,768.94
  • XRTX N/A
  • Revenue Next Year
  • ADTX N/A
  • XRTX N/A
  • P/E Ratio
  • ADTX N/A
  • XRTX N/A
  • Revenue Growth
  • ADTX N/A
  • XRTX N/A
  • 52 Week Low
  • ADTX $0.81
  • XRTX $0.66
  • 52 Week High
  • ADTX $14,800.00
  • XRTX $2.98
  • Technical
  • Relative Strength Index (RSI)
  • ADTX 49.24
  • XRTX 46.43
  • Support Level
  • ADTX $0.81
  • XRTX $0.73
  • Resistance Level
  • ADTX $1.29
  • XRTX $0.82
  • Average True Range (ATR)
  • ADTX 0.11
  • XRTX 0.06
  • MACD
  • ADTX 0.02
  • XRTX -0.00
  • Stochastic Oscillator
  • ADTX 76.00
  • XRTX 43.37

About ADTX Aditxt Inc.

Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.

About XRTX XORTX Therapeutics Inc.

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Share on Social Networks: